This is from “A Patient’s Guide to BAT”. When they refer to AR it means the androgen receptors.

One of the key things to emphasize is that BAT was developed to work against CRPC cells. These cells have adaptively fine‐tuned the AR to high levels in response to low testosterone produced by androgen deprivation. This high level of AR, paradoxically, makes the prostate cancer cell vulnerable to sudden exposure to high amounts of testosterone. In this case, “too much of a bad thing can be a good thing.” Flooding the prostate cancer cell with testosterone creates a problem for the cell. Now it has to suddenly deal with too much androgen bound to AR. This high level “gums up the works” so to speak. It disrupts the ability of the prostate cancer cell to divide as part of the growth cycle. In response, the prostate cancer cell either stops growing or dies.